SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines

Abstract

COVID-19 has rapidly spread all over the world, progressing into a pandemic. This situation has urgently impelled many companies and public research institutes to concentrate their efforts on research for effective therapeutics. Here, we outline the strategies and targets currently adopted in developing a vaccine against SARS-CoV-2. Based on previous evidence and experience with SARS and MERS, the primary focus has been the Spike protein, considered as the ideal target for COVID-19 immunotherapies.

Cited by papers we hold 5

• A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations · 2022
  No notice
• SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants · 2021
  No notice
• Perspectives on RNA Vaccine Candidates for COVID-19 · 2021
  Not checked
• Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines · 2020
  No notice
• Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.